Mitochondrial density and training: zone 2 vs HIIT

Key takeaways

• Endurance training raises mitochondrial density. Holloszy's classic 1967 rodent work, and the human biopsy studies that followed, showed higher mitochondrial respiratory enzyme activity (cytochrome oxidase, succinate oxidase) and oxidative capacity per gram of muscle .
• PGC-1α is the master transcriptional coactivator of mitochondrial biogenesis, switched on by muscle contraction through AMPK, calcium / calcineurin (CaMK), and beta-adrenergic signaling .
• Both moderate-intensity continuous training (MICT) and interval training drive mitochondrial adaptation. Sprint intervals reach similar gains on about a tenth of the total work (Burgomaster 2008) , and when work is matched, higher-intensity intervals produce somewhat greater mitochondrial content than MICT .
• Zone 2's value is that you can sustain a lot of it. Seiler's polarization work puts elite endurance training near an 80/20 split of low-intensity to high-intensity volume .
• Mitochondrial-targeted compounds (MOTS-c, elamipretide, urolithin A, NMN, NR) have preclinical and small-trial signals. Elamipretide won accelerated FDA approval as FORZINITY for Barth syndrome in 2025 , but none is approved for athletic performance or longevity, and none substitutes for training volume.

What the biopsy data actually show

The muscle-biopsy work on training and mitochondria goes back to John Holloszy in the 1960s. His 1967 rat study established that endurance training raises the respiratory enzyme activity of skeletal muscle, including cytochrome oxidase and succinate oxidase, and increases oxidative capacity per gram of tissue . Citrate synthase became the field's standard marker of mitochondrial content in the human work that followed.

Later human studies using percutaneous needle biopsy and stable-isotope tracers refined the picture. Mitochondrial protein synthesis rises after both moderate-intensity and higher-intensity endurance work, and the signaling pathways behind it (AMPK, PGC-1α, mTOR, calcineurin) are now reasonably well mapped in the review literature .

Modern measurement leans on high-resolution respirometry of permeabilized muscle fibers (the Pesta and Gnaiger protocol), 31P-MRS for in vivo phosphocreatine recovery kinetics, and electron microscopy for mitochondrial morphology . Respirometry has produced the cleanest training-adaptation data of the past 15 years.

PGC-1α and the mitochondrial-biogenesis program

PGC-1α (peroxisome proliferator-activated receptor gamma coactivator 1-alpha) is the master transcriptional coactivator of mitochondrial biogenesis. Muscle contraction turns it on through several inputs: AMPK activation, calcium signaling (calcineurin and CaMK), and beta-adrenergic stimulation. Once active, PGC-1α drives the transcription factors (NRF1, NRF2, TFAM) that coordinate the nuclear and mitochondrial genes a new mitochondrion needs .

The acute response scales with intensity. In a study that matched total energy expenditure between a long low-intensity bout and a shorter high-intensity one, PGC-1α mRNA rose 3.8-fold after the low-intensity session and 10.2-fold after the high-intensity session three hours later, tracking with AMPK and CaMKII activation . The chronic adaptation, more mitochondrial enzyme content, is the sum of these acute spikes over weeks of training.

The 'zone 2' question, fairly stated

In the popular framing, zone 2 maps to a heart-rate range near the top of fat oxidation, just under the first lactate threshold, roughly a pace you can hold a conversation at. The case for banking volume there is that it trains type I fiber oxidative capacity while keeping systemic stress low enough to hold high weekly hours for years.

Head-to-head trials of polarized training (mostly easy, a little hard, little in the middle) against threshold-heavy training in trained athletes generally favor the polarized approach for performance . Mitochondrial enzyme content rises across both moderate-continuous and interval protocols in randomized human work, so the gap between them is narrower than zone-2-only proponents suggest .

Seiler's polarization research puts an 80/20 split of low-intensity to high-intensity work in elite endurance athletes, with the low-intensity share sitting below the first lactate threshold, essentially zone 2 . For trained athletes, 80/20 is closer to the truth than all zone 2.

HIIT vs MICT trials

• Burgomaster 2008 (J Physiol): six weeks of low-volume sprint interval training (four to six 30-second all-out efforts, 3x/week, about 1.5 hours a week) matched 40 to 60 minutes of continuous cycling at 65 percent VO2peak done 5x/week (about 4.5 hours) on mitochondrial markers, PGC-1α protein, and exercise capacity, on roughly a tenth of the total work .
• Gillen 2016 (PLoS ONE): a 12-week comparison of sprint interval training versus MICT in sedentary men found similar gains in VO2peak (about 19 percent in both) and mitochondrial content (citrate synthase) despite five-fold less exercise volume .
• MacInnis and Gibala 2017 (J Physiol review): when protocols are matched for total work, mitochondrial content increases are greater after higher-intensity interval training than after MICT; sprint intervals reach MICT-like content on much less volume, so the practical edge is time efficiency .
• Granata 2018 (Sports Med review): relative exercise intensity is an important determinant of the change in mitochondrial respiratory function, and mitochondrial content and respiratory function do not always move together .

What actually changes mitochondrial density and function

• Total weekly aerobic time across the year, with the dose-response steepest for people starting from a low base.
• Enough intensity to trigger AMPK and PGC-1α signaling, which moderate continuous, threshold, or interval work can all reach.
• Recovery between hard sessions; chronic under-recovery blunts the adaptation.
• Fuel around hard sessions. Chronic low energy availability impairs training adaptation and recovery in the RED-S literature .
• Resistance training does less for mitochondrial density than endurance work but still adds some, especially in mixed-modality programs.
• Cold and heat exposure may add small adaptations, but the effect is minor next to training volume.

Where supplements and peptides sit

Mitochondrial-targeted compounds sit mostly in the preclinical and early-translational literature. One now has an FDA approval, but for a rare disease, not for performance or longevity.

• MOTS-c: a 16-amino-acid mitochondrial-derived peptide. Preclinical work shows metabolic and skeletal-muscle benefits in mice; human data are limited to small pharmacokinetic studies, and it has no FDA approval .
• Elamipretide (SS-31): a cardiolipin-binding mitochondrial peptide. Its phase 3 trial in primary mitochondrial myopathy (MMPOWER-3) was terminated after the blinded phase missed its primary endpoints . In 2025 the FDA gave it accelerated approval as FORZINITY to improve muscle strength in Barth syndrome, the first approved mitochondria-targeted drug, on a knee-extensor-strength endpoint rather than any performance or longevity claim .
• Urolithin A: an ellagitannin metabolite made by gut bacteria, sold as Mitopure. A randomized trial in older adults found improved muscle endurance and better plasma mitochondrial and inflammatory biomarkers, though maximal ATP production did not change .
• NAD precursors (NMN, NR): covered in the NAD precursors evidence snapshot. They modestly raise NAD+ with plausible downstream mitochondrial effects, but hard outcome-trial data are thin.

Editorial summary

Mitochondrial density rises with training. Moderate continuous work and intervals both do the job; which mix wins depends on the training time you have and the base you start from. Zone 2 is useful because it is sustainable at volume, and the magic-intensity framing oversells it. No supplement or peptide replaces the training in healthy adults.

For research and educational purposes only. Not medical advice.

pepSmart has not commissioned independent clinical review of this article.

More on how we write and source these pieces: Editorial process and contributor disclosure and Sourcing posture.

Spot an error? Email corrections via /about.

Sources: 16 entries, all primary canon (PubMed, ClinicalTrials.gov, FDA / DailyMed), last reviewed 2026-07-08.

Related tools

• Body-recomp simulator overview - Public overview of the Pro body-recomposition simulator.